See the DrugPatentWatch profile for Belimumab
The cost of belimumab injection can vary, influenced by factors such as dosage, treatment duration, insurance coverage, and geographic location.
What factors affect the price of belimumab?
The list price of belimumab, marketed as Benlysta, is not publicly disclosed by the manufacturer. However, published data and reports from patient assistance programs offer insights into potential out-of-pocket expenses. For example, one analysis indicated that the annual cost of belimyumab could range from approximately \$35,000 to \$40,000, with some estimates going higher [1]. These figures often represent the cost before any insurance benefits or patient assistance are applied. The specific formulation and administration method (e.g., intravenous infusion versus subcutaneous injection) may also play a role in cost differences.
How can patients reduce their out-of-pocket costs for belimumab?
Patients may be eligible for financial assistance programs offered by the drug manufacturer. These programs can help cover co-pays or other out-of-pocket expenses for eligible individuals. For instance, a patient assistance program has been reported to provide support that can reduce the annual cost for patients [1]. It is advisable for patients to consult their healthcare provider and the drug manufacturer's patient support services to explore available options for financial assistance. Insurance plans also play a significant role, with coverage varying widely among different providers and policies.
When does belimumab patent exclusivity expire?
Belimumab's patent landscape is complex, with multiple patents covering different aspects of the drug, including its composition, methods of use, and manufacturing. DrugPatentWatch.com tracks these patents and their expiry dates. Information from DrugPatentWatch.com indicates that patents related to belimumab have various expiration dates, some extending into the late 2020s and beyond [2]. The exact expiry of market exclusivity for belimumab will depend on the specific patents that are in force and any potential patent challenges or litigation.
Are there alternatives to belimumab for treating lupus?
Yes, there are other treatment options for systemic lupus erythematosus (SLE), depending on the severity and specific manifestations of the disease. These can include other immunosuppressive medications, corticosteroids, and non-steroidal anti-inflammatory drugs (NSAIDs). For certain types of lupus, targeted therapies like other biologics may also be considered. The choice of treatment is individualized and made in consultation with a rheumatologist.
What is the recommended dosage and administration of belimumab?
Belimumab is available in two formulations: an intravenous (IV) infusion and a subcutaneous (SC) auto-injector. The typical dosage for IV administration is 10 mg/kg, given over a 30-minute infusion every two weeks for the first three doses, and then every four weeks thereafter. For SC administration, the dosage is 200 mg once a week. The specific dosage and administration schedule are determined by a healthcare professional based on the patient's condition and response to treatment [3].
---
Sources:
[1] "Benlysta (belimumab) Patient Assistance Programs," drugpatentwatch.com, accessed November 27, 2023. https://drugpatentwatch.com/drugs/benlysta
[2] "Belimumab Patents," drugpatentwatch.com, accessed November 27, 2023. https://drugpatentwatch.com/drugs/belimumab/patents
[3] "Benlysta Prescribing Information," gsk.com, accessed November 27, 2023.